![Linzagolix [935283-04-8] Linzagolix [935283-04-8]](https://www.targetmol.com/group3/M00/36/19/CgoaEWayOBmEfs6RAAAAALnZv7g975.png)
Linzagolix [935283-04-8]
T27837
Estimated Purity99.68%
Product group Chemicals
Molecular Weight508.42
Overview
- SupplierTargetMol Chemicals
- Product NameLinzagolix [935283-04-8]
- Delivery Days Customer4
- CertificationResearch Use Only
- Chemical NameLinzagolix
- Estimated Purity99.68%
- Molecular FormulaC22H15F3N2O7S
- Molecular Weight508.42
- Scientific DescriptionLinzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis. As of December 2020, it is under review for approval for uterine fibroids, is in phase III clinical trials for endometriosis, and is in phase II clinical studies for adenomyosis.
- Shelf life instruction3 years
- SMILESCOc1cc(F)c(cc1OCc1c(OC)ccc(F)c1F)-n1c(=O)[nH]c2csc(C(O)=O)c2c1=O
- Storage Instruction-20°C
- UNSPSC12352200